promising cancer treatment targets rare flaw
Last Updated : GMT 09:40:38
Themuslimchronicle, themuslimchronicle
Themuslimchronicle, themuslimchronicle
Last Updated : GMT 09:40:38
Themuslimchronicle, themuslimchronicle

At a major cancer conference

Promising Cancer Treatment Targets Rare Flaw

Themuslimchronicle, themuslimchronicle

Themuslimchronicle, themuslimchroniclePromising Cancer Treatment Targets Rare Flaw

An experimental cancer medicine
New York - Muslimchronicle

An experimental cancer medicine called larotrectinib has shown promise treating a diverse range of cancers in people young and old, researchers said at a major cancer conference in the United States.

The treatment targets a genetic abnormality which is often found in rare cancers -- including salivary gland cancer, juvenile breast cancer, and a soft tissue cancer known as infantile fibrosarcoma -- which are particularly difficult to treat.

This abnormality also occurs in about 0.5 percent to one percent of many common cancers.

In the study released at the American Society of Clinical Oncology conference, 76 percent of cancer patients -- both children and adults with 17 different kinds of cancer -- responded well to the medicine.

A total of 79 percent were alive after one year. The study is ongoing.

Twelve percent went into complete remission from their cancer.

The clinical trial included 55 patients -- 43 adults and 12 children. All had advanced cancers in various organs, including the colon, pancreas and lung, as well as melanoma.

"These findings embody the original promise of precision oncology: treating a patient based on the type of mutation, regardless of where the cancer originated," said lead study author David Hyman, chief of early drug development at Memorial Sloan Kettering Cancer Center in New York. 

"We believe that the dramatic response of tumors with TRK fusions to larotrectinib supports widespread genetic testing in patients with advanced cancer to see if they have this abnormality."

Made by Loxo Oncology Inc., larotrectinib is a selective inhibitor of tropomyosin receptor kinase (TRK) fusion proteins.

TRK proteins are a product of a genetic abnormality when a TRK gene in a cancer cell fuses with one of many other genes, researchers said.

The U.S. Food and Drug Administration has not yet approved the treatment for widespread use.

The treatment was well tolerated by patients, and the most common side effects were fatigue and mild dizziness.

"If approved, larotrectinib could become the first therapy of any kind to be developed and approved simultaneously in adults and children, and the first targeted therapy to be indicated for a molecular definition of cancer that spans all traditionally-defined types of tumors," said Hyman.

Source: AFP

themuslimchronicle
themuslimchronicle

GMT 07:55 2017 Tuesday ,26 December

Florida orange industry hit

GMT 08:18 2017 Monday ,18 December

Judge Temporarily Blocks New rules

GMT 00:27 2017 Saturday ,02 December

Serious health risks waste burning

GMT 12:13 2017 Tuesday ,17 October

Mass Cholera Vaccinations Begin

GMT 07:54 2017 Saturday ,19 August

UN demands civilian access
Themuslimchronicle, themuslimchronicle
Themuslimchronicle, themuslimchronicle

Name *

E-mail *

Comment Title*

Comment *

: Characters Left

Mandatory *

Terms of use

Publishing Terms: Not to offend the author, or to persons or sanctities or attacking religions or divine self. And stay away from sectarian and racial incitement and insults.

I agree with the Terms of Use

Security Code*

promising cancer treatment targets rare flaw promising cancer treatment targets rare flaw

 



Themuslimchronicle, themuslimchronicle

GMT 08:26 2018 Tuesday ,23 January

Five things to know about Davos

GMT 21:30 2017 Wednesday ,01 November

New York Times’ third-quarter revenue up 6.1%

GMT 11:09 2017 Friday ,24 November

Berlin police seeking more missing John Lennon items

GMT 06:34 2017 Saturday ,09 December

Rockets down Jazz for eighth straight NBA win

GMT 23:25 2017 Thursday ,16 February

Pakistan adds 16 new fighter jets to its fleet

GMT 10:50 2018 Tuesday ,23 January

Saudi university to open driving school for women

GMT 03:31 2017 Saturday ,07 January

Sharjah launches award for refugee support

GMT 21:54 2016 Wednesday ,01 June

December 21 - January 18

GMT 16:05 2017 Monday ,24 April

Sharapova's return divides rivals

GMT 13:50 2012 Sunday ,22 January

Egyptians can now remove any regime

GMT 07:26 2017 Sunday ,23 July

70 villagers kidnapped in Afghanistan
Themuslimchronicle, themuslimchronicle
Themuslimchronicle, themuslimchronicle
 
 Themuslimchronicle Facebook,themuslimchronicle facebook  Themuslimchronicle Twitter,themuslimchronicle twitter Themuslimchronicle Rss,themuslimchronicle rss  Themuslimchronicle Youtube,themuslimchronicle youtube  Themuslimchronicle Youtube,themuslimchronicle youtube

Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2023 ©

Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2023 ©

muslimchronicle muslimchronicle muslimchronicle muslimchronicle
themuslimchronicle themuslimchronicle themuslimchronicle
themuslimchronicle
بناية النخيل - رأس النبع _ خلف السفارة الفرنسية _بيروت - لبنان
themuslimchronicle, themuslimchronicle, themuslimchronicle